While Drugs for Neglected Diseases initiative (DNDi) drives the R&D for neglected diseases, we collaborate with pharmaceutical companies at multiple stages, including sourcing promising molecules
Leading orthopaedic experts call for equitable insurance coverage to patients for accessing advanced, precision-driven joint replacement technologies
The summit will bring together 1,200+ delegates, 100+ international faculty from 25 countries
Ajax's lead program, AJ1-11095, is a first-in-class Type II JAK2 inhibitor currently in Phase 1 clinical development, with first proof-of-concept clinical data to be presented later in 2026
Manoj has over two decades of experience in healthcare operations and biomedical engineering
The event showcased latest breakthroughs in minimally invasive surgery, organ-preservation strategies, and targeted therapies
The project entails a total planned capital expenditure of approximately Rs. 500 - 520 crore
The PRIOH-1 study met its primary endpoint, delivering statistically significant and clinically meaningful improvements in lesion healing
The initiative is being led through the Bank’s CSR programme, Parivartan, in partnership with the Indian Cancer Society
The decision positions Yartemlea as the first and only approved inhibitor of the lectin pathway of complement
Subscribe To Our Newsletter & Stay Updated
